C2N Diagnostics LLC announced it has entered a partnership with Grupo Fleury to bring blood-based tests that aid in early Alzheimer's diagnosis to patient care in Brazil. The partnership will aim to introduce the most advanced set of plasma biomarkers to detect changes that indicate the presence of Alzheimer's disease pathology in patients experiencing memory difficulties. The announcement of the partnership between C2N and Grupo Fleury is timely on World Alzheimer's Day, part of World Alzheimer's Month every September that focuses on uniting people from all corners of the globe to raise disease awareness, and to highlight the importance of early diagnosis and post-diagnosis support based on the latest innovations in care.

It follows two other C2N international initiatives. The company is taking part in the Global Health Care Preparedness Project with the Davos Alzheimer's Collaborative, where Brazil is one of six countries with sites that rely on C2N's PrecivityAD blood test to increase timely, accurate diagnosis of Alzheimer's.